A Study to Evaluate the Effect of Fingolimod on CSF Biomarkers Levels of Inflammation and Degeneration Following Switch from Other Disease Modifying Treatments in Patients with Relapsing Remitting Multiple Sclerosis (RRMS)

Trial Profile

A Study to Evaluate the Effect of Fingolimod on CSF Biomarkers Levels of Inflammation and Degeneration Following Switch from Other Disease Modifying Treatments in Patients with Relapsing Remitting Multiple Sclerosis (RRMS)

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2016

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 26 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top